← ANALYST RATINGS · TIPRANKS
Coherus Biosciences (CHRS): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $8.50, the highest $10.00, the lowest $7.00. The average is +758.6% from the last price of $0.99.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.00 | Hold | +1.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $7.00 | Buy | +607.1% | Reiterated | 21.09.26on TipRanks 13:55 | −0.1%next day −5.1% · 5 days −15.8% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $4.00 | Buy | +304.0% | Reiterated | 06.08.26on TipRanks Aug 7 17:05 | −12.6%next day −0.2% · 5 days −11.1% | ↗ |
| Paul Jeng★★★★★★★★★★#9457 · hits 52% · avg −1.9% | Guggenheim | $12.00 → $10.00−16.7% | Buy | +910.1% | Reiterated | 06.08.26on TipRanks Aug 7 07:50 | −12.6%next day −0.2% · 5 days −11.1% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $10.00 | Buy | +910.1% | Reiterated | 06.08.26on TipRanks 09:01 | −12.6%next day −0.2% · 5 days −11.1% | ↗ |
| Michael Nedelcovych★★★★★★★★★★#9548 · hits 48% · avg −1.2% | TD Cowen | — | Buy | — | Reiterated | 28.05.26on TipRanks 14:45 | −1.2%next day −3.9% · 5 days −4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Coherus Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.75 at a price of $1.21 (+540.5%); now: $7.75 at $0.99 (+682.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.22 (from $-0.26 to $-0.19). Last quarter: $-0.22.
Sales
Next quarter’s sales estimate — $16M (from $15M to $17M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Coherus Biosciences
- CEO: Dennis Lanfear
- Employees: 144
- 333 Twin Dolphin Drive, Redwood City, CA, 94065, US
- www.coherus.com
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2
Data from the stock’s TipRanks forecast page, read 90 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗